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Despite reduction in cardiovascular (CV) events and end-organ damage with the current pharmacologic strategies, CV disease
remains the primary cause of death in the world. Pharmacological therapies based on the renin angiotensin system (RAS)
blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success
the prevalence of end-organ damage and residual risk remain still high. Novel approaches must be discovered for a more eﬀective
treatment of residual CV remodeling and risk. The ACE2/Ang-(1–9) axis is a new and important target to counterbalance the
vasoconstrictive/proliferative RAS axis. Ang-(1–9) is hydrolyzed slower than Ang-(1–7) and is able to bind the Ang II type 2
receptor. We review here the current experimental evidence suggesting that activation of the ACE2/Ang-(1–9) axis protects the
heart and vessels (and possibly the kidney) from adverse cardiovascular remodeling in hypertension as well as in heart failure.
1.Introduction
All epidemiological studies show that the risk of adverse
cardiovascular (CV) outcomes, such as stroke, myocardial
infarction (MI), heart failure (HF), and kidney disease [1],
increase progressively with increasing blood pressure (BP).
On the other hand, clinical trials demonstrate that lowering
BP reduces such risks [1]. All antihypertensive medications
lower BP, but speciﬁc drug classes display eﬀects beyond
BP reduction (pleiotropic eﬀects) that might contribute to
cardiovascular risk reduction.
Remodeling of the cardiovascular structure occurs in
response, not only to changes in BP and ﬂow, but also to
modiﬁcations in the neurohormonal environment, in which
the rennin-angiotensin-aldosterone system (RAAS) exerts a
most predominant inﬂuence [2].
The RAAS is a major regulator of BP [3, 4]. In ad-
dition, the RAAS has a role in the vascular response to
injury and inﬂammation [4]. Chronic RAAS activation,
through both angiotensin (Ang) II and aldosterone, leads to
hypertension and perpetuates a cascade of proinﬂammatory,
prothrombotic, and atherogenic eﬀects associated with end-
organ damage [3, 4]. Based on these facts, several drugs have
been developed that work by (a) reduction of Ang II levels,
(b) inhibition of the Ang II type 1 receptor (AT1R), (c)
blockade of the aldosterone receptor, and (d) renin receptor
blockade [5, 6]. During the last 25 years several clinical trials
have shown the beneﬁts with these drugs that inhibit the
RAAS with regard to BP reduction, regression of cardiac
hypertrophy, prevention of kidney damage and reduction of
cardiovascular morbidity reduction in hypertensive patients.
Besides, with most of these RAAS blockers, quality of life as
well as survival has been signiﬁcantly improved in patients
with heart failure. Consequently, the RAAS is currently a
main therapeutic target in hypertension treatment [3, 4].
Aggressive BP control improves outcomes in patients with
CV disease, stroke, and nephropathy and might have beneﬁ-
cial eﬀects beyond BP lowering [7].
Despite the reduction of CV events and end-organ dam-
age with the current pharmacologic strategies, CV disease
remains the primary cause of death in the world, and more
than 94,000 Americans annually experience progression to
end-stage renal disease (ESRD). As population ages, the
proportion aﬀected by end-organ damage is expected to
grow [8] .T h u s ,i ti sm o s tr e l e v a n tt oﬁ n dn e wm o l e c u l e s2 International Journal of Hypertension
in order to prevent and reduce hypertension as well as
pathologic CV and kidney remodeling and dysfunction. In
this regard, activation of the new ACE2/Ang-(1–9) pathway
seems to counterbalance the damage due to the RAAS system
activation.
We review here the current experimental evidence sug-
gesting that activation of the ACE2/Ang-(1–9) pathway pro-
tects the heart and vessels (and possibly the kidney) from
adverse cardiovascular remodeling in hypertension as well as
in heart failure.
2. Angiotensin-ConvertingEnzyme 2
The discovery of angiotensin-converting enzyme homo-
logue, ACE2, added further complexity to the main axis of
the RAAS, in which Ang II and its forming enzyme ACE play
major roles [9, 10]. A growing body of evidence points to a
possible promising role for this new member of the RAAS
by opposing to the eﬀects of the main axis [11, 12]. ACE2
has dramatically changed the direction of cardiovascular and
renalresearchin viewof thepivotal roleofthis enzymein the
regulation of the RAAS [12, 13].
ACE2 is the newest member of the RAAS and shares
approximately 40% similarity with the somatic form of ACE
[9, 10]. ACE2 is a membrane-bound carboxypeptidase and
its cellular and tissue distribution is diﬀerent from that of
ACE.WhileACEisexpressedintheendotheliumthroughout
the vasculature, ACE2 is distributed in tissues with the most
abundant expression in heart, kidney, lung, small intestine,
and testis [14]. ACE2 can be released into the circula-
tion and urine by shedding [15]. Tumor necrosis factor-
alpha-converting enzyme (TACE/ADAM17) is the sheddase
responsible for the ectodomain cleavage and shedding of
ACE2 [16].
However, normal ACE2 enzymatic activity in plasma is
very low, probably due to the presence of an endogenous
inhibitor [17–19]. ACE2 is diﬀerent from ACE in both sub-
strate speciﬁcity and functions [9, 20, 21]. ACE2 can form
(a) Ang-(1–7) through hydrolysis of Ang II and (b) Ang-(1–
9) through hydrolysis of Ang I. This last reaction is negligibly
slow and is several hundred times slower than Ang II hydrol-
ysis by ACE2 to form Ang(1–7)—a vasodepressor peptide
counterbalancing the vasopressor eﬀect of Ang II [20, 21].
Ang-(1–7) can be subsequently converted to Ang-(1–5) by
ACE [9, 20] or by neutral endopeptidases [9], while Ang-
(1–9) may be converted to Ang-(1–7) by ACE [9]. There is
little evidence proving the existence of alternative hydrolysis
of Ang-(1–9) to Ang II in some tissues. Drummer et al.
[22] proved that homogenates of rat kidney, and in a lesser
extent of lung, convert Ang-(1–9) to Ang II due to an ACE-
independent aminopeptidase and N-like carboxypeptidase.
Singh et al. [23] conﬁrmed that the pathway Ang I-Ang-
(1–9)-Ang II really exists in glomeruli of streptozotocin-
induced diabetes mellitus rats. Moreover, in human heart
tissue the main products of Ang I degradation are both Ang-
(1–9) and Ang II generated by heart chymase, ACE and
a poorly identiﬁed carboxypeptidase A [24]. Although the
data proving the existence of alternative pathways of Ang II
production, in clinical practice we can still block only ACE
or AT1R.
ACE2 does not act on bradykinin metabolism and its
activity is not inhibited by classic ACE inhibitors (ACEIs)
[9]. Thus it has been proposed that ACE2 activity may
counterbalance the eﬀects of ACE by preventing the accu-
mulation of Ang II in tissues where both ACE2 and ACE
are expressed [25, 26]. ACE2 has several biological substrates
and it is considered a multifunctional enzyme. Acting as a
monocarboxypeptidase, it cleaves several other non-RAAS
peptides which have roles in maintaining cardiovascular
homeostasis such as (des-Arg9)-bradykinin, a member of
the kininogen-kinin system [13]. (des-Arg9)-Bradykinin is
formed from bradkinin by the action of carboxypeptidases
and is an agonist of the B1 receptor, which is induced
after tissue injury [27]. Bradykinin, a vasodilator which acts
through the B2 receptor, is produced from its precursor
kininogen by kallikrein and is degraded by ACE [13]. While,
degradation of bradykinin by ACE is known to be an
important aspect of BP regulation, the signiﬁcance of the
degradation of (des-Arg9)-bradykinin by ACE2 remains to
be established. In addition to (des-Arg9)-bradykinin, ACE2
is also able to degrade apelin-13, a peptide proposed to cause
vasoconstriction and known to regulate ﬂuid homeostasis,
and other non-RAAS peptides such as kinetensin, dynorphin
A and neurotensin [20].
For a long time, Ang-(1–7) was thought to be devoid of
biological activity, in spite of early reports on biological
eﬀects [28]. The importance of Ang-(1–7) was emphasized
by the discovery of ACE2. Ang-(1–7) has been shown to
release vasopressin as eﬀectively as Ang II from neuro-
h y p o p h y s e a le x p l a n t s[ 28] and to have actions opposing
those of Ang II, namely vasodilation, antitrophic eﬀects and
implications of vasodilation caused by bradykinin [29, 30].
Several experiments suggest an important interaction
between Ang-(1–7) and prostaglandin-bradykinin-nitric
oxide (NO) systems. Ang-(1–7) binds to the Mas receptor
(G protein-coupled receptor) which mediates vasodilating
and antiproliferative actions of this peptide [31]. The Mas
receptor can hetero-oligomerize with the AT1 receptor and
acts as a physiological antagonist of Ang II [32]. Studies
revealed that Ang-(1–7) activated endothelial nitric oxide
synthase and NO production via Akt-dependent pathways
[33]. Furthermore, Tallant et al. [34] showed that the pres-
ence of an antisense probe directed against Mas abolished
the Ang-(1–7)-induced inhibition of protein synthesis in
cardiomyocytes. This study also revealed that Ang-(1–7)
decreased serum-stimulated ERK1/ERK2 mitogen-activated
protein kinase activity, a response that was blocked by D-Ala
7-Ang-(1–7), an antagonist of Mas receptor.
Ang II binds with high aﬃnity to two diﬀerent receptor
subtypes—AT1R and AT2R—which are members of the
seven-transmembrane-domain G-protein-coupled receptors
(GPCR) superfamily, through Gq and Gi, respectively [35].
Whereas the AT1R mediates most of the recognized actions
of Ang II, it appears that the AT2R opposes, in part, to the
eﬀects mediated by the AT1R. As the AT2R is expressed in
adult tissues in smaller amounts than the AT1R, the actions
and cell signaling of AT2R have been less well characterizedInternational Journal of Hypertension 3
than those of AT1R [36–38]. Current knowledge suggests
that AT2R stimulation mediates vasodilation, antigrowth,
proapoptotic and antiinﬂammatory eﬀects [39, 40]. Hence,
the AT2R can modulate cardiovascular remodeling as well as
progression of atherosclerosis.
AT2R stimulation activates the NO-cGMP-dependent
pathway [41]. This occurs either directly or indirectly
through bradykinin or by increased endothelial NOS
activity or expression. AT2R activation is associated with
phosphorylation of JNK, PTPs, IκBα (inhibitor of NF-
κB), and the transcription factor ATF2, and dephospho-
rylation of p38MAPK, ERK1/2, and STAT3, which are
linked to antiproliferative and antiinﬂammatory eﬀects
and apoptosis [38, 42–44]. AT2R may induce relaxation
by opening large-conductance Ca2+-activated K+ channels
(BKCa) [45] and by negative regulation of the vascular
Rho A/Rho kinase pathway. The AT2R also enhances the
activity of tyrosine phosphatases and vanadate-sensitive
phosphatases MKP1 (DUSP1), SHP1 (PTPN6) and PP2A
[46, 47].
3. Ang-(1–9)
There is little information in the literature with respect
to Ang-(1–9) probably because this peptide was initially
thoughttobeactiveonlyafterconversiontoAng-(1–7).Ang-
(1–9) can be generated by several carboxypeptidase-type
enzymes including ACE2 or cathepsin A [48, 49]. Ang-(1–
9) is present in healthy volunteers, in patients or in animals
treatedwithACEinhibitors(ACEIs)orAT1receptorblockers
(ARBs) [50–52], and its circulating levels are increased by
pathological conditions (i.e., early after MI) [51]. However,
very little is currently known about Ang-(1–9) biological
eﬀects [50, 53].
InitialstudiesshowedthatincubationofChinesehamster
ovary cells (CHO) with Ang-(1–9) potentiated the release of
arachidonic acid by [Hyp3Tyr(Me)8]BK, elevated [Ca2]i and
also resensitized the B2 receptor desensitized by BK [48]. At
the same time, Jackman et al. [54] showed in CHO cells and
in human pulmonary endothelial cells that Ang-(1–9) was
signiﬁcantlymoreactivethanAng-(1–7)enhancingtheeﬀect
of an ACE-resistant bradykinin analogue on the B2 receptor
and that Ang-(1–9) also augmented arachidonic acid and
NO release by kinin [54].
Some studies have suggested that Ang-(1–9) may be an
endogenous inhibitor of ACE. Donoghue et al. [9] proposed
that Ang-(1–9) is a competitive inhibitor of ACE because
it is by itselfan ACE substrate. Under conditions of ACE
inhibition, such as after long-term administration of an
ACEI in rats, Ang-(1–9) levels increased in plasma and
kidney[50,53].ThisincreaseinAng-(1–9)steady-statelevels
could be due to decreased catabolism of Ang-(1–9) by ACE.
Conversely, the increased levels of Ang-(1–9) could be due
to increased production by ACE2 as a result of increased
availability of Ang I substrate. These results indicate that an
alternate pathway of Ang I metabolism by ACE2 exists and
that this pathway may be ampliﬁed in the presence of ACE
inhibitors.
To determine whether Ang-(1–9) is active per se or it
becomes active only after conversion to Ang-(1–7), Chen
et al. [55] examined the metabolism of Ang I, Ang-(1–9)
and Ang-(1–7) in stably transfected CHO cells that express
human ACE and human bradykinin B2 receptors coupled
to green ﬂuorescent protein (B2GFP). They found that Ang-
(1–9) was hydrolyzed 18 times slower than Ang I and 30%
slower than Ang-(1–7). Ang-(1–9) inhibited ACE and it
resensitizedthedesensitizedB2GFPreceptors,independently
of ACE inhibition [55]. This is reﬂected by release of
arachidonic acid through a mechanism involving cross-talk
between ACE and B2 receptors. They concluded that Ang-
(1–9) enhanced bradykinin activity, probably by acting as an
endogenous allosteric modiﬁer of the ACE and B2 receptor
complex. Therefore, when ACE inhibitors block conversion
of Ang I, other enzymes like ACE2 can still release Ang
I metabolites like Ang-(1–9) and enhance the eﬃcacy of
ACEIs.
Recently, Flores-Mu˜ noz et al. [56] using radioligand
binding assays observed that Ang-(1–9) is able to bind
the Ang II type 2 receptor (AT2R) (pKi = 6.28 ± 0.1).
They demonstrated that Ang-(1–9) and not Ang II, aﬀected
hypertrophy through the AT2R, as PD123319 (an AT2
receptor blocker) did not alter Ang II-mediated growth but
did block the eﬀects of Ang-(1–9). Despite having ∼100-
fold lower aﬃnity than Ang II for the AT2R [57], the
selective AT2R activity of Ang-(1–9) is not inconsistent
with current pharmacological models of G protein-coupled
receptor signalling and activation. Indeed, the concept of
functional selectivity, where individual receptor ligands have
the capacity to selectively stabilize conformations which
lead to distinct signalling outcomes [57–59], is supported
by a previous study in which the critical amino acids and
the mode of binding of ligands at the AT1R and AT2R
were investigated [60]. While agonist activation of the
AT1R was particularly sensitive to peptide modiﬁcations that
disrupted contact points between Ang II and its receptor,
substitutions within Ang II were far better tolerated by
the AT2R [60]. The AT2R exists in a relaxed conformation
and Ang II therefore binds to multiple indistinct contact
points [60]. Since Ang-(1–9) contains the entire Ang II
sequence plus a C-terminal histidine, these observations
indicate that this diﬀerence may stabilize the AT2R in a
conformation able to counteract hypertrophic signalling in
cardiomyocytes. Flores-Mu˜ noz et al. [56] did not observe
functional competition between Ang II and Ang-(1–9) at
the AT2R and they concluded that that Ang-(1–9) is able
to antagonize Ang II signalling in cardiomyocytes selectively
via the AT2R, highlighting that Ang-(1–9), along with Ang-
(1–7), makes up part of the counter-regulatory arm of
the RAS. What remains to be determined is the down-
streamsignallingeﬀectsfromAng-(1–9).Preliminarystudies
indicate that the classical pathways via PKC translocation
and ERK1/2 activation [61–63]a r en o td i ﬀerent between
Ang II-, Ang-(1–7)- and Ang-(1–9) stimulated cells. Since
the downstream signalling from the AT2R is unclear at
present, future studies will be required to establish these
mechanisms.4 International Journal of Hypertension
4. Role of the ACE2/Ang-(1–9)Axis
in Hypertension
Crackower et al. [64] were the ﬁrst to test ACE2 as the gene
underlying the blood pressure locus on the X chromosome.
They showed reduced expression of renal ACE2 in the
salt-sensitive Sabra hypertensive rat compared with the
normotensive rat. Both spontaneously hypertensive rats
(SHR) and spontaneously hypertensive stroke-prone rats
(SHRSP) rats showed reduced renal ACE2 protein levels
compared with the normotensive Sabra and Wistar Kyoto
(WKY) strains. Two other groups conﬁrmed some of these
ﬁndings showing lower renal ACE2 mRNA, protein, and
activityintheSHRcomparedtoWKYrats[65,66].However,
other investigators were unable to detect any diﬀerence in
renal ACE2 mRNA, protein, and activity between adult
hypertensive rats and their normotensive controls [67].
Rentzsch et al. [68], assessed in SHRSP (that display
reducedACE2mRNAandproteinexpressioncomparedwith
control animals in the kidney) the role of ACE2 in the
pathogenesisofhypertension.Theygeneratedtransgenicrats
onaSHRSPgeneticbackgroundexpressingthehumanACE2
in vascular smooth muscle cells by the use of the SM22
promoter, called SHRSP-ACE2. In these transgenic rats,
vascular smooth muscle cells (VSMC) expression of human
ACE2 was conﬁrmed by RNase protection, real-time RT-
PCR, and ACE2 activity assays. Transgene ACE2 expression
leads to signiﬁcantly increased circulating levels of Ang-
(1–7), a prominent product of ACE2. Mean arterial blood
pressure was reduced in SHRSP-ACE2 compared to SHRSP
rats, and the vasoconstrictive response to intraarterial
administration of Ang II was attenuated. The latter eﬀectwas
abolished by previous administration of an ACE2 inhibitor.
To evaluate the endothelial function in vivo, endothelium-
dependent and endothelium-independent agents such as
acetylcholine and sodium nitroprusside, respectively, were
applied to the descending thoracic aorta and blood pressure
was monitored. Endothelial function turned out to be
signiﬁcantly improved in SHRSP-ACE2 rats compared to
SHRSP. These data indicate that vascular ACE2 overex-
pression in SHRSP reduces hypertension probably by local
Ang II degradation and by improving endothelial function
[68].
A target gene therapy strategy holds signiﬁcant potential
to translate the available fundamental research of ACE2
into therapeutics. In fact, initial animal experiments have
been extremely encouraging. For example, in SHR, viral-
mediated ACE2 overexpression in the heart decreased high
BP [69]. This strategy also preserved cardiac function,
as well as left ventricular wall motion and contractility,
and attenuated left ventricular wall thinning induced by
myocardial infarction [70]. ACE2 overexpression in the
rostral ventrolateral medulla causes signiﬁcant decreases in
BP and heart rate (HR) [71].
Compared with ACEIs and ARBs, the targeting of ACE2
has the following potential therapeutic advantages, ﬁrst, it
degradates both Ang I to generate Ang-(1–9) and Ang II
to generate Ang-(1–7). Thus, targeting ACE2 would not
only produce the antihypertrophic peptide Ang-(1–9) [52]
and the vasoprotective/antiproliferative peptide Ang-(1–
7) [72–74], but would also inﬂuence the vasoconstric-
tive/proliferative eﬀects of the ACE/Ang II/AT1R axis [75].
Second, it is a multifunctional enzyme with many bio-
logically active substrates [9, 20]. Third, unlike ARB/ACEI
therapy, ACE2 is an endogenous regulator of the RAS [75].
Fourth, it is a part of the vasodilatory/antiproliferative
axis of the RAS [20] and ﬁfth, although treatment with
ACEIs or ARBs indirectly increases ACE2 expression, direct
activation of this enzyme could result in a better outcome
in cardiovascular diseases [68, 75]. Thus, the activation
of the ACE2 axis may be a novel therapeutic strategy in
hypertension.
So far, all attention has been focused on Ang-(1–7),
that opposes the pressor, proliferative, proﬁbrotic, and pro-
thrombotic actions mediated by Ang II [76]. Experimental
and clinical studies have demonstrated a role for the Ang-
(1–7)/ACE2/Mas axis in the evolution of hypertension, the
regulation of cardiovascular and renal function, and the
progression of cardiovascular and renal disease including
diabetic nephropathy [77]. Additional evidence suggests that
a reduction in the expression and activity of this vasode-
pressor component may be a critical factor in mediating
the progression of cardiovascular and renal disease. These
ﬁndings support a role for the Ang-(1–7)/ACE2/Mas axis
and, in particular, on its putative role as an ACE-Ang
II-AT1 receptor counter-regulatory axis within the RAS
[76, 77].
Recently, the alternative angiotensin peptide, Ang-(1–
9) has shown relevant biological functions. Ocaranza et al.
[51] have observed increased ACE2 activity and Ang-(1–9)
plasma levels in MI and sham rats treated with enalapril for
8 weeks while circulating Ang-(1–7) levels did not change in
any phase after MI [51]( Figure 1). These ﬁndings support
the hypothesis that, in this second arm of the RAS, ACE2
through Ang-(1–9) instead of Ang-(1–7), could act as a
counterregulator of the ﬁrst arm, where ACE catalyzes the
formation of Ang II.
Besides, in experimental hypertension (DOCA salt mod-
el) and in normotensive sham animals, RhoA/Rho-kinase
inhibition (a signaling pathway thatparticipates in patholog-
ical cardiovascular and renal remodeling and also in blood
pressure regulation) by fasudil reduced BP and increased
vascular and plasma ACE2 enzymatic activity. At the same
time,fasudilreducedAngIIandincreasedAng-(1–9)plasma
levels (Figure 2)[ 78]. No modiﬁcations were observed here
in Ang-(1–7) levels despite increased ACE2 levels with
RhoA/Rho-kinase inhibition [78]. Thus, RhoA/Rho-kinase
inhibition, by increasing eNOS and/or by reducing both
ACE and Ang II, does not activate the Ang-(1–7) pathway.
This novel eﬀect of RhoA/Rho-kinase inhibition on both
ACE2 expression and Ang-(1–9) levels might additionally
contribute to the antihypertensive eﬀects of RhoA/Rho-
kinase inhibitors. Besides, these results strongly suggest that
in this experimental model, hypertension is more dependent
on ACE2 and Ang-(1–9) levels than on ACE and Ang II
levels. Therefore, this second RAAS axis through ACE2 and
Ang-(1–9) could be an important target for the treatment of
hypertension.International Journal of Hypertension 5
Figure 1: Plasma levels of Ang-(1–7), Ang-(1–9) and Ang II in rats
with myocardial infarction treated with the ACE inhibitor enalapril
(8 weeks). Increased plasma levels of Ang-(1–9) were observed
in rats with myocardial infarction treated with the ACE inhibitor
enalapril. Myocardial infarction was induced by coronary artery
ligation. Data are presented as mean ± SEM (n = 12/group). AMI:
acute myocardial infarction, E: enalapril. ∗P<0.05 compared to
both Sham and untreated myocardial infarction groups; ∗∗P<0.05
comparedtobothShamandenalapril-treatedmyocardialinfarction
groups. (adapted with permission from [51]).
5. Role of ACE2/Ang-(1–9)Axisin
Vascular Remodeling
The vascular wall is continuously exposed to hemodynamic
forces such as the luminal pressure and shear stress. Changes
in these forces, either physiological or pathological, lead
to functional and/or structural alterations of the vascular
wall [79]. Acute changes in hemodynamic forces can modify
vessel diameter. Chronic changes in hemodynamic forces
result in structural alterations of the vessel wall, indicated by
changes in wall diameter and thickness. In addition, changes
in vascular structure are not solely determined by hemody-
namic forces [80], but also by inﬂammatory responses and
changes in extracellular matrix components [81]. Structural
changes of the medial layer of the vascular wall during
hypertension are termed “eutrophic remodeling” [82]a n d
subsequently translate to other vascular pathologies. This
involves an inward encroachment of the arterial wall thereby,
reducing the diameter of the lumen [83].
Several RAAS components are involved in neointimal
formation after vascular endothelial damage [84]. In partic-
ular, Rakugi et al. [85] observed that vascular endothelial
damage results in the induction of vascular ACE. Their
results suggested that inhibition of vascular ACE might be
critical in the prevention of restenosis after balloon injury.
Patients with previously untreated essential hypertension
and eutrophic inward remodeling appears to respond to
antihypertensive medication. Reduction in BP with drugs
that block the RAAS such as ACEIs [86–88]o rA R B s[ 86, 87,
89] and calcium channel antagonists [90] are able to reverse
the eutrophic inward remodeling [88].
The protein and mRNA of ACE2 are expressed in human
coronary arteries and arterioles and the vasa vasorum of
most organs [9, 91]. Recently, ACE2 expression has also been
Figure 2: Plasma levels of Ang-(1–7), Ang-(1–9) and Ang II in
DOCA salt hypertensive rats treated with the Rho kinase inhibitor
fasudil. Increased plasma levels of Ang-(1–9) were observed in
DOCA salt hypertensive rats treated with the Rho kinase inhibitor
fasudil.Fasudil(100mh/kg/day)bygavagewasadministeredduring
3 weeks, starting on the third week after DOCA administration.
Data are presented as mean ± SEM (n = 8–11/group). DOCA:
deoxycorticosterone, F: fasudil. ∗P<0.05 compared to both Sham
and untreated DOCA groups (adapted with permission from [78]).
observed in the large conduit arteries (aorta and carotid)
in the HR [92]. ACE2 localizes preferentially in endothelial
cells and arterial smooth muscle cells (SMCs) [9, 91]. As
for the role of ACE2 in vascular remodeling, the eﬀect of
ACE2 on neointima formation has not yet been studied, but
Ang-(1–7) infusion after balloon-catheter injury of the rat
carotid artery reduced neointima formation [93]. This eﬀect
was probably mediated by its inhibition of vascular SMC
proliferation [94]. In hypertensive animal models, ACE2
mRNA and protein were associated with immunoreactive
Ang-(1–7) in the large conduit arteries of SHRs. Treatment
with an ARB induced a ﬁvefold increase in ACE2 mRNA and
was associated with a signiﬁcant increase in aortic Ang-(1–7)
protein expression. This eﬀect was associated with a decrease
in aortic medial thickness, suggesting that this may be a
protective mechanism in the prevention of cardiovascular
events during hypertension [94]. Igase et al. [95] showed
that ACE2 protein is expressed not only in the media of
the carotid artery but also in the neointima of the balloon-
injured carotid artery in SHR. The increase in ACE2 protein
expression in the neointima following exposure of the rats to
an ARB compared to vehicle was associated with a reduction
in neointima thickness. These results lead to the hypothesis
that there is a strong correlation between the increase in
ACE2 protein in the injured carotid artery of SHR and
vascular remodeling during blockade of Ang II receptors
[95].
There is known the prothrombotic eﬀect of Ang II
[96, 97] and the antithrombotic action of Ang-(1–7) [98]
in renovascular hypertensive rats. Thus, in this context, the
question arises whether Ang-(1–9) eﬀects are similar to
Ang II or to Ang-(1–7) in in vivo conditions. Kramkowski
et al. [99] described that Ang-(1–9) enhances electrically6 International Journal of Hypertension
stimulated thrombosis in rats and that this eﬀect was
abolished by losartan—an antagonist of the AT1 receptor.
The prothrombotic activity of Ang-(1–9) was accompanied
by the enhancement of ex vivo platelet aggregation and
in vitro Ang-(1–9) increased platelet aggregation. However,
there are some points in this paper that should be clari-
ﬁed. First, thrombus formation was initiated by electrical
stimulation producing arterial injury that is unrelated to a
clinical situation. Second, the prothrombotic eﬀect of Ang-
(1–9) was much weaker, to the prothrombotic action of
Ang II [96, 97]. Third, Ang-(1–9) slightly increased platelet
aggregation in in vitro conditions.
On the contrary Ocaranza et al. [78] showed that by
inhibiting the RhoA/Rho-kinase pathway with fasudil, gene
expression and enzymatic ACE activity and plasma levels
o fA n gI Iw e r er e d u c e d( Figure 2) and whereas aortic gene
expression and ACE2 activity were importantly increased.
Simultaneously, plasma levels of Ang-(1–9) (Figure 2),
mRNA eNOS levels increased and the aortic overexpression
of the remodeling promotion proteins TGF-β1, PAI-1, and
MCP-1 as well as the increased aortic NADPH oxidase
activity and O2− production were reduced, as a consequence
ofdirectRhoA/Rho-kinaseinhibition[100].Thisnoveleﬀect
of RhoA/Rho-kinase inhibition on ACE2 gene expression,
enzymatic activity, and Ang-(1–9) levels might additionally
contribute to its beneﬁts in hypertension, atherosclerosis,
and in cardiovascular and renal pathologic remodeling. This
is the ﬁrst observation concerning a pharmacologic ACE2
and Ang-(1–9) levels activator, both in normotensive and in
hypertensive animals, one of the most interesting ﬁndings of
that study (Figure 2). Additionally, in experimental hyper-
tension, direct RhoA/Rho-kinase inhibition also normalizes
overexpression of genes that promote vascular remodeling.
Interestingly, the observed changes in ACE/ACE2 and in
Ang-(1–9) levels were present only during fasudil treatment
both in sham and in the DOCA hypertensive rats [78].
Thus, vascular remodeling could be more dependent on
the tissue ACE2/Ang-(1–9) axis than on Ang-(1–7) levels in
normotensive as well as in hypertensive rats.
In vessels, new members of the RAS have been detected,
including ACE2, Ang-(1–7) and Mas. Vascular ACE2 is func-
tionally active and generates Ang-(1–7) from Ang II. Ang-
(1–7) is found in the endothelium and vascular wall [101–
103] and immunohistochemical staining shows abundant
presence in aortic perivascular adventitial tissue [104, 105].
Ang-(1–7), by binding to receptor Mas on endothelial cells,
opposes Ang II actions by mediating vasodilation, growth-
inhibition, antiinﬂammatory responses, antiarrhythmogenic
and antithrombotic eﬀects [33, 68] through NOS-derived
NO production, activation of protein tyrosine phosphatases,
reduced MAPK activation and inhibition of NADPH
oxidase-derived generation of reactive oxygen species (ROS)
[106, 107]. Overexpression of ACE2 in the vascular wall of
SHR is associated with improved endothelial function and
attenuated development of hypertension [68]. Ang-(1–7)-
Mas can hetero-oligomerize with AT1R, thereby inhibiting
Ang II actions. The ACE2/Ang-(1–7)-Mas axis is now
considered as a counter-regulatory system to the ACE-
Ang II-AT1R axis in the vasculature [107], although some
evidence indicates that Ang-(1–7) may also promote ﬁbrosis
and inﬂammation in certain conditions [108, 109].
6. Role of the ACE2/Ang-(1–9)Axisin
CardiacRemodeling
After myocardial injury or in response to chronically in-
creased hemodynamic load, cardiac mass increases as a
result of cardiomyocyte hypertrophy and ventricular wall
thickening. Initially these changes are compensatory mech-
anisms which help to maintain ejection performance and
heart function. With continued hemodynamic overload
the heart becomes dilated and its walls thinner, resulting
in a geometry that contributes to systolic dysfunction by
increasing wall stress [110]. At the cellular level, cardiac
myocytesincreaseinsize(hypertrophy),rearrangewithinthe
myocardial matrix (cell slippage), and die, to be replaced by
ﬁbrous tissue, which include ﬁbroblasts and collagen. These
changes are collectively referred to as “remodeling” [111].
Cardiac remodeling has been consistently associated with an
impaired prognosis in patients with hypertension, MI and
chronic heart failure (CHF) [112].
Despite recent advances in our understanding of the
ACE2/Ang-(1–7)/axis, the functional role of ACE2 in the
heart is somewhat controversial. Crackower et al. [64]
originally reported a progressive reduction in LV contractile
function in ACE2-null mice without signiﬁcant changes in
ﬁbrosis, left ventricular and cardiac myocyte hypertrophy, or
in mean arterial pressure [64]. Interestingly, whereas plasma
and tissue levels of Ang II were increased, a decrease in blood
pressure was only observed in 6-month-old male ACE−/−
homozygote mice but not in age-matched females or 3-
month-old males. Conversely, Gurley et al. [113]r e p o r t e d
that ACE2 deletion enhanced the susceptibility to Ang II-
induced hypertension but had no eﬀect on cardiac structure
or function [113]. Huentelman et al. [114] showed that the
ACE2 overexpression protects the heart from Ang II-induced
hypertrophyandﬁbrosis.Morerecently,inSHRhypertensive
rats D´ ıez-Freire et al. by using lentiviral-based ACE2 gene
transfer, attenuated cardiac ﬁbrosis and hypertrophy [70]
and also improved LV and remodeling after experimental
MI [115]. Finally, Yamamoto et al. [116] reported that
ACE2 deletion exacerbated pressure overload-induced car-
diac dysfunction and remodeling that was associated with
increased intracardiac Ang II levels and AT1R activation.
The reasons for these discrepancies seem to be: (a) the
genetic background of the mice used for ACE2 gene deletion
[113], (b) global versus tissue-speciﬁc ACE2 manipulation,
or (c) the cardiac responses were monitored under basal or
pathophysiological conditions.
In MI Ocaranza et al. [51] observed that (a) circulating
and LV enzymatic activities of ACE2 were downregulated
in the long-term phase of LV dysfunction in rats, (b) these
eﬀects were prevented by the conventional ACE inhibitor
enalapril, (c) plasma Ang-(1–9) levels were signiﬁcantly
increased when MI rats or sham-operated rats were treated
with enalapril for 8 weeks but circulating Ang-(1–7) levels





























Ang-(1–9)-dependent mechanisms that antagonize the cardiovascular remodeling eﬀects of Ang II. ACE2 can directly cleave Ang I to form
Ang-(1–9). This peptide activates the AT2R to initiate signaling pathways that antagonize AT1R-mediated tyrosine kinase cascades. In this
simpliﬁed scenario, Ang-(1–9) increases SHP-1 tyrosine phosphatase activity to inactivate src-dependent signaling. AT2R activation also
acts other pathways such as NO-AKT. AT1R: Ang II type 1 receptor; AT2R: Ang II type 2 receptor; ERK1/2: extracellular signal-regulated
kinase 1/2; JAK: Janus-activated kinase; MAPK: mitogen-activated protein kinase; p38: p38 MAPK; PKC: protein kinase C; STAT: signal
transducer and activator of transcription; NO: nitric oxide; SHP-1: protein tyrosine phosphatase SH2 domain-containing phosphatase 1;
MEK: mitogen/ERK kinase. Solid arrows indicates activation broken arrows indicates inactivation.
ﬁndings, it was proposed in this model of HF, that Ang-(1–
9) rather than Ang-(1–7) acts as a counterregulator of Ang II
[51].
Recently, in MI rats randomized to receive either vehicle,
the ACEI enalapril, or the ARB candesartan for 8 weeks,
Ocaranzaet al. [52] observed that both drugs prevented LVH
and increased plasma Ang-(1–9) levels by several folds. Ang-
(1–9) levels correlated negatively with diﬀerent LVH markers
with or without adjustment for BP reduction. This eﬀect
was speciﬁc as neither Ang-(1–7), Ang II nor bradykinins
were correlated with LVH. Chronic administration of Ang-
(1–9) to MI rats by osmotic minipumps versus vehicle for
two weeks decreased plasma Ang II levels, inhibited ACE
a c t i v i t ya n da l s op r e v e n t e dc a r d i a cm y o c y t eh y p e r t r o p h y .
Because there are in vitro evidences that the incubation of
Ang-(1–9) with ACE generates Ang-(1–7) [9], and Ang-(1–
7) negatively regulates hypertrophy [34, 117], the authors
used the Ang-(1–7) receptor blocker A779 to investigate
whether Ang-(1–7) could mediate the eﬀects of Ang-(1–9).
Even though A779 was bioactive, with signiﬁcant increase
in circulating Ang-(1–7) levels by 2.7 fold, this compound
did not modify the Ang-(1–9)-dependent suppression of
cardiac myocytes hypertrophy induced by MI [52]. In in
vitro experiments with cardiac myocytes incubated with
norepinephrine (10μM) or with IGF-1 (10nM), Ang-(1–9)
also prevented hypertrophy and this eﬀect was not modiﬁed
by the coincubation with Ang-(1–9) and A779 [52].
To further understand the role of Ang-(1–9) compared
to Ang-(1–7) in cardiomyocyte hypertrophy, Flores-Mu˜ noz
et al. [56] studied Ang-(1–9) eﬀects in rat neonatal H9c2
andinrabbitleftventricularcardiomyocytes.Cardiomyocyte
hypertrophy was stimulated with Ang II or vasopressin,
signiﬁcantly increasing cell size by approximately 1.2-fold
as well as stimulating expression of the hypertrophy gene
markers atrial natriuretic peptide, brain natriuretic peptide,
β-myosin heavy chain and myosin light chain (2- to 5-
fold). Both Ang-(1–9) and Ang-(1–7) were able to block
hypertrophy induced by either agonist. The eﬀects of Ang-
1–9) were not inhibited by captopril, supporting previous
evidence that Ang-(1–9) acts independently of Ang-(1–7).
The authors investigated receptor signalling via angiotensin
type 1 and type 2 receptors (AT1R, AT2R) and Mas. The
AT1R antagonist losartan blocked Ang II-induced, but not
vasopressin-induced, hypertrophy. Losartan did not block
the antihypertrophic eﬀects of Ang-(1–9), or Ang-(1–7) on
vasopressin-stimulated cardiomyocytes. The Mas antagonist
A779 eﬃciently blocked the antihypertrophic eﬀects of Ang-
(1–7), without aﬀecting Ang-(1–9). Furthermore, Ang-(1–7)
activity was also inhibited in the presence of the bradykinin
type 2 receptor antagonist HOE140, without aﬀecting Ang-
(1–9). Moreover, Flores-Mu˜ noz et al. [56] observed that the
AT2R antagonist PD123,319 abolished the antihypertrophic
eﬀectsofAng-(1–9),withoutaﬀectingAng-(1–7),suggesting
Ang-(1–9) signals via the AT2R. Radioligand binding assays8 International Journal of Hypertension
demonstrated that Ang-(1–9) was able to bind the AT2R
(pKi = 6.28 ± 0.1). The data indicate that ACE2/Ang-(1–
9) axis, acting as a counterregulator of Ang II, is an eﬀective,
and possibly direct novel anticardiac hypertrophy axis.
7. Conclusions
Pharmacological treatments based on the RAS blockade are
used extensively for the treatment of hypertension and CV
remodeling. However, in spite of their success in pharma-
cological blockade of the RAS, the prevalence of end-organ
damage has risen steadily in the last several decades. These
observations indicate that novel and innovative approaches
mustbeusedinanattempttopromoteamoreeﬀectivetreat-
ment for the residual CV remodeling. In this environment,
the ACE2/Ang-(1–9) axis is an important target, that is criti-
cal in tipping the balance of vasoconstrictive/proliferative to
vasodilatory/antiproliferative axis of the RAS. Conceptually,
the ACE2/Ang-(1–9)/AT2 axis balances the adverse eﬀects of
the ACE-Ang II-AT1 receptor axis (Figure 3). Accumulating
evidence suggests that ACE2 expression and Ang-(1–9) levels
are altered in diastolic and systolic dysfunction and remodel-
ing and the activation of the ACE2/Ang-(1–9) axis protects
the heart and vessels from cardiovascular remodeling. In
conclusion, the noncanonical RAS arm has new biological
eﬀector Ang-(1–9) to counterregulate the classical RAS.
Acknowledgments
This work was supported by Fondo Nacional de Desarrollo
Cient´ ıﬁco y Tecnol´ ogico (Fondecyt) Grants 1100874 and
1085208.
References
[1] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh
report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003.
[2] H.D.IntenganandE.L.Schiﬀrin,“Structureandmechanical
properties of resistance arteries in hypertension: role of ad-
hesion molecules and extracellular matrix determinants,”
Hypertension, vol. 36, no. 3, pp. 312–318, 2000.
[3] A. W. J. H. Dielis, M. Smid, H. M. H. Spronk et al., “The
prothrombotic paradox of hypertension: role of the renin-
angiotensin and kallikrein-kinin systems,” Hypertension, vol.
46, no. 6, pp. 1236–1242, 2005.
[4] C. M. Ferrario, “Role of angiotensin II in cardiovascular
disease therapeutic implications of more than a century of
research,” Journal of the Renin-Angiotensin-Aldosterone Sys-
tem, vol. 7, no. 1, pp. 3–14, 2006.
[ 5 ]M .R .W e i r ,“ E ﬀects of renin-angiotensin system inhibition
end-organ protection: can we do better?” Clinical Therapeu-
tics, vol. 29, no. 9, pp. 1803–1824, 2007.
[6] A. H. J. Danser, “(Pro)renin receptors: are they biologically
relevant?” Current Opinion in Nephrology and Hypertension,
vol. 18, no. 1, pp. 74–78, 2009.
[7] M. R. Weir, “Targeting mechanisms of hypertensive vascular
disease with dual calcium channel and renin-angiotensin
system blockade,” Journal of Human Hypertension, vol. 21,
no. 10, pp. 770–779, 2007.
[8] P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K.
Whelton, and J. He, “Global burden of hypertension: analysis
of worldwide data,” The Lancet, vol. 365, no. 9455, pp. 217–
223, 2005.
[9] M. Donoghue, F. Hsieh, E.Baronas et al., “A novel angiotens-
in-convertingenzyme-relatedcarboxypeptidase(ACE2)con-
verts angiotensin I to angiotensin 1-9,” Circulation Research,
vol. 87, no. 5, pp. E1–E9, 2000.
[10] S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie,
and A. J. Turner, “A human homolog of angiotensin-con-
verting enzyme: cloning and functional expression as a cap-
topril-insensitive carboxypeptidase,” Journal of Biological
Chemistry, vol. 275, no. 43, pp. 33238–33243, 2000.
[11] U. Danilczyk, U. Eriksson, M. A. Crackower, and J. M. Pen-
ninger, “A story of two ACEs,” Journal of Molecular Medicine,
vol. 81, no. 4, pp. 227–234, 2003.
[12] G. Y. Oudit, M. A. Crackower, P. H. Backx, and J. M.
Penninger, “The role of ACE2 in cardiovascular physiology,”
Trends in Cardiovascular Medicine, vol. 13, no. 3, pp. 93–101,
2003.
[ 1 3 ]A .J .T u r n e r ,S .R .T i p n i s ,J .L .G u y ,G .I .R i c e ,a n dN .M .
Hooper, “ACEH/ACE2 is a novel mammalian metallocar-
boxypeptidase and a homologue of angiotensin-converting
enzyme insensitive to ACE inhibitors,” Canadian Journal of
Physiology and Pharmacology, vol. 80, no. 4, pp. 346–353,
2002.
[14] F. Gembardt, A. Sterner-Kock, H. Imboden et al., “Organ-
speciﬁc distribution of ACE2 mRNA and correlating pepti-
dase activity in rodents,” Peptides, vol. 26, no. 7, pp. 1270–
1277, 2005.
[15] S. Epelman, K. Shrestha, R. W. Troughton et al., “Soluble
angiotensin-converting enzyme 2 in human heart failure:
relation with myocardial function and clinical outcomes,”
Journal of Cardiac Failure, vol. 15, no. 7, pp. 565–571, 2009.
[16] D. W. Lambert, M. Yarski, F. J. Warner et al., “Tumor necrosis
factor-α convertase (ADAM17) mediates regulated ectodo-
main shedding of the severe-acute respiratory syndrome-
coronavirus (SARS-CoV) receptor, angiotensin-converting
enzyme-2 (ACE2),” Journal of Biological Chemistry, vol. 280,
no. 34, pp. 30113–30119, 2005.
[17] K. M. Elased, T. S. Cunha, S. B. Gurley, T. M. Coﬀman, and
M. Morris, “New mass spectrometric assay for angiotensin-
converting enzyme 2 activity,” Hypertension,v o l .4 7 ,n o .5 ,
pp. 1010–1017, 2006.
[ 1 8 ]G .I .R i c e ,A .L .J o n e s ,P .J .G r a n t ,A .M .C a r t e r ,A .J .T u r n e r ,
and N. M. Hooper, “Circulating activities of angiotensin-
converting enzyme, its homolog, angiotensin-converting
enzyme 2, and neprilysin in a family study,” Hypertension,
vol. 48, no. 5, pp. 914–920, 2006.
[19] R. A. Lew, F. J. Warner, I. Hanchapola et al., “Angiotensin-
converting enzyme 2 catalytic activity in human plasma is
masked by an endogenous inhibitor,” Experimental Physiol-
ogy, vol. 93, no. 5, pp. 685–693, 2008.
[20] C. Vickers, P. Hales, V. Kaushik et al., “Hydrolysis of bio-
logical peptides by human angiotensin-converting enzyme-
related carboxypeptidase,” Journal of Biological Chemistry,
vol. 277, no. 17, pp. 14838–14843, 2002.
[21] G. I. Rice, D. A. Thomas, P. J. Grant, A. J. Turner, and N.
M. Hooper, “Evaluation of angiotensin-converting enzyme
(ACE), its homologue ACE2 and neprilysin in angiotensin
peptide metabolism,” Biochemical Journal, vol. 383, no. 1, pp.
45–51, 2004.International Journal of Hypertension 9
[22] O. H. Drummer, S. Kourtis, and H. Johnson, “Formation
of angiotensin II and other angiotensin peptides from des-
leu 10-angiotensin I in rat lung and kidney,” Biochemical
Pharmacology, vol. 37, no. 22, pp. 4327–4333, 1988.
[23] R. Singh, A. K. Singh, and D. J. Leehey, “A novel mechanism
for angiotensin II formation in streptozotocin-diabetic rat
glomeruli,” American Journal of Physiology, vol. 288, no. 6,
pp. F1183–F1190, 2005.
[24] J .O .K okkonen,J .Saarinen,andP .T .K ovanen,“R egulationof
localangiotensinIIformationinthehumanheartinthepres-
ence of interstitial ﬂuid: inhibition of chymase by protease
inhibitors of interstitial ﬂuid and of angiotensin-converting
enzyme by ANG-(1-9) formed by heart carboxypeptidase A-
like activity,” Circulation, vol. 95, no. 6, pp. 1455–1463, 1997.
[25] M. Ye, J. Wysocki, P. Naaz, M. R. Salabat, M. S. LaPointe, and
D. Batlle, “Increased ACE 2 and decreased ACE protein in
renal tubules from diabetic mice: a renoprotective combina-
tion?” Hypertension, vol. 43, no. 5, pp. 1120–1125, 2004.
[26] G. Rivi` ere, A. Michaud, C. Breton et al., “Angiotensin-con-
verting enzyme 2 (ACE2) and ACE activities display tissue-
speciﬁcsensitivitytoundernutrition-programmedhyperten-
sion in the adult rat,” Hypertension, vol. 46, no. 5, pp. 1169–
1174, 2005.
[27] M. Kakoki, R. W. McGarrah, H. S. Kim, and O. Smithies,
“Bradykinin B1 and B2 receptors both have protective roles
in renal ischemia/reperfusion injury,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 104, no. 18, pp. 7576–7581, 2007.
[28] M. T. Schiavone, R. A. S. Santos, K. B. Brosnihan, M. C.
Khosla, and C. M. Ferrario, “Release of vasopressin from the
rat hypothalamo-neurohypophysial system by angiotensin-
(1-7) heptapeptide,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 85, no. 11, pp.
4095–4098, 1988.
[ 2 9 ]R .A .S o u z aD o sS a n t o s ,K .T .P a s s a g l i o ,J .B .P e s q u e r o ,M .
Bader, and A. C. Sim˜ oes E Silva, “Interactions between angi-
otensin-(1-7), kinins, and angiotensin II in kidney and blood
vessels,” Hypertension, vol. 38, no. 3, pp. 660–664, 2001.
[30] L. G. Maia, M. C. Ramos, L. Fernandes, M. H.C. De Car-
valho, M. J. Campagnole-Santos, and R. A.S. Dos Santos,
“Angiotensin-(1-7) antagonist A-779 attenuates the poten-
tiation of bradykinin by captopril in rats,” Journal of Cardio-
vascular Pharmacology, vol. 43, no. 5, pp. 685–691, 2004.
[31] R. A. S. Santos, A. C. Simoes e Silva, C. Maric et al., “Angi-
otensin-(1-7) is an endogenous ligand for the G protein-
coupled receptor Mas,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 100, no. 14, pp.
8258–8263, 2003.
[32] E. Kostenis, G. Milligan, A. Christopoulos et al., “G-protein-
coupled receptor Mas is a physiological antagonist of the
angiotensin II type 1 receptor,” Circulation, vol. 111, no. 14,
pp. 1806–1813, 2005.
[33] W. O. Sampaio, R. A. S. Dos Santos, R. Faria-Silva, L.
T. Da Mata Machado, E. L. Schiﬀr i n ,a n dR .M .T o u y z ,
“Angiotensin-(1-7) through receptor Mas mediates endothe-
lial nitric oxide synthase activation via Akt-dependent path-
ways,” Hypertension, vol. 49, no. 1, pp. 185–192, 2007.
[34] E. A. Tallant, C. M. Ferrario, and P. E. Gallagher, “Angiotens-
in-(1-7) inhibits growth of cardiac myocytes through activa-
tion of the mas receptor,” American Journal of Physiology, vol.
289, no. 4, pp. H1560–H1566, 2005.
[35] E. Kaschina and T. Unger, “Angiotensin AT1/AT2 receptors:
regulation, signalling and function,” Blood Pressure, vol. 12,
no. 2, pp. 70–88, 2003.
[36] M.Horiuchi,M.Akishita,andV.J.Dzau,“Recent progressin
angiotensin II type 2 receptor research in the cardiovascular
system,” Hypertension, vol. 33, no. 2, pp. 613–621, 1999.
[ 3 7 ]C .S a v o i a ,F .T a b e t ,G .Y a o ,E .L .S c h i ﬀrin, and R. M. Touyz,
“Negative regulation of RhoA/Rho kinase by angiotensin
II type 2 receptor in vascular smooth muscle cells: role in
angiotensin II-induced vasodilation in stroke-prone sponta-
neously hypertensive rats,” Journal of Hypertension, vol. 23,
no. 5, pp. 1037–1045, 2005.
[38] C. Hu, A. Dandapat, J. Chen et al., “Over-expression of
angiotensin II type 2 receptor (agtr2) reduces atherogenesis
and modulates LOX-1, endothelial nitric oxide synthase and
heme-oxygenase-1 expression,” Atherosclerosis, vol. 199, no.
2, pp. 288–294, 2008.
[39] R. M. Touyz and E. L. Schiﬀrin, “Signal transduction mech-
anisms mediating the physiological and pathophysiological
actions of angiotensin II in vascular smooth muscle cells,”
Pharmacological Reviews, vol. 52, no. 4, pp. 639–672, 2000.
[40] D. Henrion, N. Kubis, and B. I. L´ evy, “Physiological and
pathophysiological functions of the AT2 subtype receptor of
angiotensin II from large arteries to the microcirculation,”
Hypertension, vol. 38, no. 5, pp. 1150–1157, 2001.
[41] P. M. Abadir, R. M. Carey, and H. M. Siragy, “Angiotensin
AT2 receptors directly stimulate renal nitric oxide in Brad-
ykinin B2-receptor-null mice,” Hypertension, vol. 42, no. 4 I,
pp. 600–604, 2003.
[ 4 2 ]C .S a v o i a ,T .E b r a h i m i a n ,Y .H e ,J .P .G r a t t o n ,E .L .S c h i ﬀrin,
and R. M. Touyz, “Angiotensin II/AT2 receptor-induced
vasodilation in stroke-prone spontaneously hypertensive rats
involves nitric oxide and cGMP-dependent protein kinase,”
Journal of Hypertension, vol. 24, no. 12, pp. 2417–2422, 2006.
[43] A. Dandapat, C. P. Hu, J. Chen et al., “Over-expression of
angiotensin II type 2 receptor (agtr2) decreases collagen ac-
cumulation in atherosclerotic plaque,” Biochemical and Bio-
physical Research Communications, vol. 366, no. 4, pp. 871–
877, 2008.
[44] P. Brassard, F. Amiri, and E. L. Schiﬀrin, “Combined angi-
otensin II type 1 and type 2 receptor blockade on vascular
remodeling and matrix metalloproteinases in resistance ar-
teries,” Hypertension, vol. 46, no. 3, pp. 598–606, 2005.
[45] C. Dimitropoulou, R. E. White, L. Fuchs, H. Zhang, J. D.
Catravas,andG.O.Carrier,“AngiotensinIIrelaxesmicroves-
sels via the AT2 receptor and Ca2+-activated K+ (BKCa)
channels,” Hypertension, vol. 37, no. 2 I, pp. 301–307, 2001.
[46] M. Horiuchi, W. Hayashida, T. Kambe, T. Yamada, and V. J.
Dzau, “Angiotensin type 2 receptor dephosphorylates Bcl-2
by activating mitogen-activated protein kinase phosphatase-
1 and induces apoptosis,” Journal of Biological Chemistry, vol.
272, no. 30, pp. 19022–19026, 1997.
[47] K. Bedecs, N. Elbaz, M. Sutren et al., “Angiotensin II type
2 receptors mediate inhibition of mitogen-activated protein
kinase cascade and functional activation of SHP-1 tyrosine
phosphatase,” Biochemical Journal, vol. 325, no. 2, pp. 449–
454, 1997.
[48] E. G. Erd¨ o s ,H .L .J a c k m a n ,V .B r o v k o v y c h ,F .T a n ,a n dP .
A. Deddish, “Products of angiotensin I hydrolysis by human
cardiac enzymes potentiate bradykinin,” Journal of Molecular
and Cellular Cardiology, vol. 34, no. 12, pp. 1569–1576, 2002.
[ 4 9 ]F .J .W a r n e r ,A .I .S m i t h ,N .M .H o o p e r ,a n dA .J .T u r n e r ,
“Angiotensin-converting enzyme-2: a molecular and cellular
perspective,” Cellular and Molecular Life Sciences, vol. 61, no.
21, pp. 2704–2713, 2004.10 International Journal of Hypertension
[ 5 0 ]H .J o h n s o n ,S .K o u r t i s ,J .W a t e r s ,a n dO .H .D r u m m e r ,
“Radioimmunoassay for immunoreactive [des-Leu10]-an-
giotensin I,” Peptides, vol. 10, no. 3, pp. 489–492, 1989.
[51] M.P.Ocaranza,I.Godoy,J.E.Jaliletal.,“Enalaprilattenuates
downregulation of angiotensin-converting enzyme 2 in the
late phase of ventricular dysfunction in myocardial infarcted
rat,” Hypertension, vol. 48, no. 4, pp. 572–578, 2006.
[52] M. P. Ocaranza, S. Lavandero, J. E. Jalil et al., “Angiotensin-
(1-9) regulates cardiac hypertrophy in vivo and in vitro,”
Journal of Hypertension, vol. 28, no. 5, pp. 1054–1064, 2010.
[53] O. H. Drummer, S. Kourtis, and H. Johnson, “Eﬀect of
chronic enalapril treatment on enzymes responsible for the
catabolism of angiotensin I and formation of angiotensin II,”
Biochemical Pharmacology, vol. 39, no. 3, pp. 513–518, 1990.
[54] H.L.Jackman,M.G.Massad,M.Sekosanetal.,“Angiotensin
1-9 and 1-7 release in human heart role of cathepsin A,”
Hypertension, vol. 39, no. 5, pp. 976–981, 2002.
[ 5 5 ]Z .C h e n ,F .T a n ,E .G .E r d¨ os, and P. A. Deddish, “Hydrolysis
of angiotensin peptides by human angiotensin I-converting
enzyme and the resensitization of B2 kinin receptors,” Hy-
pertension, vol. 46, no. 6, pp. 1368–1373, 2005.
[56] M. Flores-Mu˜ noz, N. J. Smith, C. Haggerty, G. Milligan, and
S. A. Nicklin, “Angiotensin1-9 antagonises pro-hypertrophic
signallingincardiomyocytesviatheangiotensintype2recep-
tor,” Journal of Physiology, vol. 589, no. 4, pp. 939–951, 2011.
[57] S. Galandrin, G. Oligny-Longpr´ e, and M. Bouvier, “The eva-
sive nature of drug eﬃcacy: implications for drug discovery,”
Trends in Pharmacological Sciences, vol. 28, no. 8, pp. 423–
430, 2007.
[58] T. Kenakin, “Functional selectivity through protean and
biased agonism: who steers the ship?” Molecular Pharmacol-
ogy, vol. 72, no. 6, pp. 1393–1401, 2007.
[59] N. J. Smith, K. A. Bennett, and G. Milligan, “When simple
agonism is not enough: emerging modalities of GPCR li-
gands,” Molecular and Cellular Endocrinology, vol. 331, no. 2,
pp. 241–247, 2011.
[60] S. I. Miura and S. S. Karnik, “Angiotensin II type 1 and type
2 receptors bind angiotensin II through diﬀerent types of
epitope recognition,” Journal of Hypertension,v o l .1 7 ,n o .3 ,
pp. 397–404, 1999.
[61] Y. Zou, I. Komuro, T. Yamazaki et al., “Protein kinase C, but
nottyrosinekinasesorRas,playsacriticalroleinangiotensin
II-inducedactivationofRaf-1kinaseandextracellularsignal-
regulated protein kinases in cardiac myocytes,” Journal of
BiologicalChemistry,vol.271,no.52,pp.33592–33597,1996.
[62] K. Vijayan, E. L. Szotek, J. L. Martin, and A. M. Samarel,
“Protein kinase C-α-induced hypertrophy of neonatal rat
ventricular myocytes,” American Journal of Physiology, vol.
287, no. 6, pp. H2777–H2789, 2004.
[63] J. Pan, U. S. Singh, T. Takahashi et al., “PKC mediates
cyclic stretch-induced cardiac hypertrophy through Rho
family GTPases and mitogen-activated protein kinases in
cardiomyocytes,” Journal of Cellular Physiology, vol. 202, no.
2, pp. 536–553, 2005.
[64] M. A. Crackower, R. Sarao, G. Y. Oudit et al., “Angiotensin-
converting enzyme 2 is an essential regulator of heart
function,” Nature, vol. 417, no. 6891, pp. 822–828, 2002.
[65] J. C. Zhong, D. Y. Huang, Y. M. Yang et al., “Upregulation of
angiotensin-converting enzyme 2 by all-trans retinoic acid in
spontaneously hypertensive rats,” Hypertension, vol. 44, no.
6, pp. 907–912, 2004.
[66] C. Tikellis, M. E. Cooper, K. Bialkowski et al., “Develop-
mental expression of ACE2 in the SHR kidney: a role in
hypertension?” Kidney International, vol. 70, no. 1, pp. 34–
41, 2006.
[67] I. Hamming, R. Kreutz, J. Sluimer et al., “Renal angiotensin-
converting enzyme 2 is unaltered in experimental hyperten-
sion,” Journal of the American Society of Nephrology, vol. 16,
article TH–PO294-TH-PO294, 2005.
[68] B. Rentzsch, M. Todiras, R. Iliescu et al., “Transgenic angi-
otensin-converting enzyme 2 overexpression in vessels of
SHRSP rats reduces blood pressure and improves endothelial
function,” Hypertension, vol. 52, no. 5, pp. 967–973, 2008.
[69] C. D´ ıez-Freire, J. V´ azquez, M. F. Correa De Adjounian et al.,
“ACE2 gene transfer attenuates hypertension-linked patho-
physiological changes in the SHR,” Physiological Genomics,
vol. 27, no. 1, pp. 12–19, 2006.
[70] S. Der Sarkissian, J. L. Grobe, L. Yuan et al., “Cardiac
overexpression of angiotensin converting enzyme 2 protects
the heart from ischemia-induced pathophysiology,” Hyper-
tension, vol. 51, no. 3, pp. 712–718, 2008.
[71] M. Yamazato, Y. Yamazato, C. Sun, C. Diez-Freire, and M. K.
Raizada, “Overexpression of angiotensin-converting enzyme
2 in the rostral ventrolateral medulla causes long-term
decrease in blood pressure in the spontaneously hypertensive
rats,” Hypertension, vol. 49, no. 4, pp. 926–931, 2007.
[72] K. B. Brosnihan, P. Li, and C. M. Ferrario, “Angiotensin-(1-
7) dilates canine coronary arteries through kinins and nitric
oxide,” Hypertension, vol. 27, no. 3, pp. 523–528, 1996.
[ 7 3 ]S .Y .O s e i ,R .S .A h i m a ,R .K .M i n k e s ,J .P .W e a v e r ,M .
C. Khosla, and P. J. Kadowitz, “Diﬀerential responses to
angiotensin-(1-7) in the feline mesenteric and hindquarters
vascular beds,” European Journal of Pharmacology, vol. 234,
no. 1, pp. 35–42, 1993.
[74] I. Porsti, A. T. Bara, R. Busse, and M. Hecker, “Release of
nitric oxide by angiotensin-(1-7) from porcine coronary en-
dothelium: implications for a novel angiotensin receptor,”
British Journal of Pharmacology, vol. 111, no. 3, pp. 652–654,
1994.
[75] J. Zhong, R. Basu, D. Guo et al., “Angiotensin-converting
enzyme 2 suppresses pathological hypertrophy, myocardial
ﬁbrosis, and cardiac dysfunction,” Circulation, vol. 122, no.
7, pp. 717–728, 2010.
[76] R. A. S. Santos, A. J. Ferreira, and A. C. Sim˜ oes E Silva,
“Recent advances in the angiotensin-converting enzyme 2-
angiotensin(1-7)-Mas axis,” Experimental Physiology, vol. 93,
no. 5, pp. 519–527, 2008.
[77] C. M. Ferrarlo, “ACE2: more of Ang-(1-7) or less Ang II?”
Current Opinion in Nephrology and Hypertension, vol. 20, no.
1, pp. 1–6, 2011.
[78] M. P. Ocaranza, P. Rivera, U. Novoa et al., “Rho kinase in-
hibition activates the homologous angiotensin-converting
enzyme-angiotensin-(1-9) axis in experimental hyperten-
sion,” Journal of Hypertension, vol. 29, no. 4, pp. 706–715,
2011.
[79] S. Heeneman, J. C. Sluimer, and M. J. A. P. Daemen, “Angiot-
ensin-converting enzyme and vascular remodeling,” Circula-
tion Research, vol. 101, no. 5, pp. 441–454, 2007.
[80] W.J.G.Hacking,E.Vanbavel,andJ.A.E.Spaan,“Shearstress
is not suﬃcient to control growth of vascular networks: Aa
model study,” American Journal of Physiology, vol. 270, no. 1,
pp. H364–H375, 1996.
[81] G. Pasterkamp, Z. S. Galis, and D. P. V. De Kleijn, “Expansive
arterial remodeling: location, location, location,” Arterioscle-
rosis, Thrombosis, and Vascular Biology,v o l .2 4 ,n o .4 ,p p .
650–657, 2004.International Journal of Hypertension 11
[82] P. I. Korner, J. A. Angus, and M. J. Mulvany, “Vascular
remodeling,” Hypertension, vol. 29, no. 4, pp. 1065–1066,
1997.
[83] J. G. R. De Mey, P. M. Schiﬀers, R. H. P. Hilgers, and M. M.
W. Sanders, “Toward functional genomics of ﬂow-induced
outward remodeling of resistance arteries,” American Journal
of Physiology, vol. 288, no. 3, pp. H1022–H1027, 2005.
[84] N. Iwai, M. Izumi, T. Inagami, and M. Kinoshita, “Induction
of renin in medial smooth muscle cells by balloon injury,”
Hypertension, vol. 29, no. 4, pp. 1044–1050, 1997.
[85] H. Rakugi, D. S. Wang, V. J. Dzau, and R. E. Pratt, “Potential
importance of tissue angiotensin-converting enzyme inhibi-
tioninpreventingneointimaformation,” Circulation,vol.90,
no. 1, pp. 449–455, 1994.
[86] D. Rizzoni, E. Porteri, G. Bettoni et al., “Eﬀects of candes-
artan cilexetil and enalapril on structural alterations and
endothelial function in small resistance arteries of sponta-
neously hypertensive rats,” Journal of Cardiovascular Phar-
macology, vol. 32, no. 5, pp. 798–806, 1998.
[87] D. Rizzoni, E. Porteri, A. Piccoli et al., “Eﬀects of losartan
and enalapril on small artery structure in hypertensive rats,”
Hypertension, vol. 32, no. 2, pp. 305–310, 1998.
[88] N. K. Thybo, N. Stephens, A. Cooper, C. Aalkjaer, A. M.
Heagerty, and M. J. Mulvany, “Eﬀect of antihypertensive
treatment on small arteries of patients with previously un-
treated essential hypertension,” Hypertension, vol. 25, no. 4 I,
pp. 474–481, 1995.
[89] E. L. Schiﬀrin, J. B. Park, H. D. Intengan, and R. M. Touyz,
“Correction of arterial structure and endothelial dysfunction
in human essential hypertension by the angiotensin receptor
antagonist losartan,” Circulation, vol. 101, no. 14, pp. 1653–
1659, 2000.
[90] E. Porteri, D. Rizzoni, A. Piccoli et al., “Eﬀects of hypotensive
and non-hypotensive doses of manidipine on structure,
responses to endothelin-1 and ICAM-1 production in mes-
enteric small resistance arteries of spontaneously hyperten-
sive rats,” Blood Pressure, vol. 7, no. 5-6, pp. 324–330, 1998.
[91] I. Hamming, W. Timens, M. L. C. Bulthuis, A. T. Lely, G.
J. Navis, and H. van Goor, “Tissue distribution of ACE2
protein, the functional receptor for SARS coronavirus. A
ﬁrst step in understanding SARS pathogenesis,” Journal of
Pathology, vol. 203, no. 2, pp. 631–637, 2004.
[92] M. Igase, W. B. Strawn, P. E. Gallagher, R. L. Geary, and C.
M. Ferrario, “Angiotensin II at1 receptors regulate ACE2 and
angiotensin-(1-7) expression in the aorta of spontaneously
hypertensive rats,” American Journal of Physiology, vol. 289,
no. 3, pp. H1013–H1019, 2005.
[93] W .B .Stra wn,C.M.F e rrario ,andE.A.T allant,“ A ngiot e nsin-
(1-7) reduces smooth muscle growth after vascular injury,”
Hypertension, vol. 33, no. 1, pp. 207–211, 1999.
[ 9 4 ]E .J .F r e e m a n ,G .M .C h i s o l m ,C .M .F e r r a r i o ,a n dE .A .
Tallant, “Angiotensin-(1-7) inhibits vascular smooth muscle
cell growth,” Hypertension, vol. 28, no. 1, pp. 104–108, 1996.
[95] M. Igase, K. Kohara, T. Nagai, T. Miki, and C. M. Ferrario,
“Increased expression of angiotensin converting enzyme 2 in
conjunction with reduction of neointima by angiotensin II
type 1 receptor blockade,” Hypertension Research, vol. 31, no.
3, pp. 553–559, 2008.
[96] A. Mogielnicki, E. Chabielska, R. Pawlak, J. Szemraj, and W.
Buczko, “Angiotensin II enhances thrombosis development
in renovascular hypertensive rats,” Thrombosis and Haemos-
tasis, vol. 93, no. 6, pp. 1069–1076, 2005.
[97] M. Kami´ nska, A. Mogielnicki, A. Stankiewicz et al., “Angi-
otensin II via AT1 receptor accelerates arterial thrombosis
in renovascular hypertensive rats,” Journal of Physiology and
Pharmacology, vol. 56, no. 4, pp. 571–585, 2005.
[98] I. Kucharewicz, R. Pawlak, T. Matys, D. Pawlak, and W.
Buczko, “Antithrombotic eﬀect of captopril and losartan is
mediated by angiotensin-(1-7),” Hypertension,v o l .4 0 ,n o .5 ,
pp. 774–779, 2002.
[99] K. Kramkowski, A. Mogielnicki, A. Leszczynska, and W.
Buczko, “Angiotensin-(1-9), the product of angiotensin I
conversion in platelets, enhances arterial thrombosis in rats,”
Journal of Physiology and Pharmacology,v o l .6 1 ,n o .3 ,p p .
317–324, 2010.
[100] P. Rivera, M. P. Ocaranza, S. Lavandero, and J. E. Jalil, “Rho
k i n a s ea c t i v a t i o na n dg e n ee x p r e s s i o nr e l a t e dt ov a s c u l a r
remodeling in normotensive rats with high angiotensin I-
converting enzyme levels,” Hypertension,v o l .5 0 ,n o .4 ,p p .
792–798, 2007.
[101] V. J. Dzau, K. Bernstein, D. Celermajer et al., “Pathophysio-
logic and therapeutic importance of tissue ACE: a consensus
report,” Cardiovascular Drugs and Therapy,v o l .1 6 ,n o .2 ,p p .
149–160, 2002.
[102] D. M. R. Silva, H. R. Vianna, S. F. Cortes, M. J. Campagnole-
S a n t o s ,R .A .S .S a n t o s ,a n dV .S .L e m o s ,“ E v i d e n c ef o ran e w
angiotensin-(1-7) receptor subtype in the aorta of Sprague-
Dawley rats,” Peptides, vol. 28, no. 3, pp. 702–707, 2007.
[103] D. Weiss, K. E. Bernstein, S. Fuchs, J. Adams, A. Synetos,
and W. R. Taylor, “Vascular wall ACE is not required for
atherogenesis in ApoE-/- mice,” Atherosclerosis, vol. 209, no.
2, pp. 352–358, 2010.
[104] R. M. K. W. Lee, M. Bader, N. Alenina, R. A. Santos, Y. J. Gao,
and C. Lu, “Mas receptors in modulating relaxation induced
by perivascular adipose tissue,” Life Sciences, vol. 89, no. 13-
14, pp. 467–472, 2011.
[105] R. M. K. W. Lee, C. Lu, L. Y. Su, and Y. J. Gao, “Endothelium-
dependent relaxation factor released by perivascular adipose
tissue,” Journal of Hypertension, vol. 27, no. 4, pp. 782–790,
2009.
[106] W. O. Sampaio, C. H. De Castro, R. A. S. Santos, E. L.
Schiﬀrin, and R. M. Touyz, “Angiotensin-(1-7) counterreg-
ulates angiotensin II signaling in human endothelial cells,”
Hypertension, vol. 50, no. 6, pp. 1093–1098, 2007.
[107] L. A. Rabelo, N. Alenina, and M. Bader, “ACE2-angiotensin-
(1-7)-Masaxisandoxidativestressincardiovasculardisease,”
Hypertension Research, vol. 34, no. 2, pp. 154–160, 2011.
[108] V. Esteban, S. Heringer-Walther, A. Sterner-Kock et al., “An-
giotensin-(1-7) and the G protein-coupled receptor Mas are
key players in renal inﬂammation,” PLoS ONE,v o l .4 ,n o .4 ,
Article ID e5406, 2009.
[109] E.Velkoska,R.G.Dean,K.Griggs,L.Burchill,andL.M.Bur-
rell, “Angiotensin-(1-7) infusion is associated with increased
blood pressure and adverse cardiac remodelling in rats with
subtotal nephrectomy,” Clinical Science, vol. 120, no. 8, pp.
335–345, 2011.
[110] M. J. Davies, “A macro and micro view of coronary vascular
insult in ischemic heart disease,” Circulation,v o l .8 2 ,n o .3 ,
pp. II38–II46, 1990.
[111] L. H. Opie, P. J. Commerford, B. J. Gersh, and M. A. Pfeﬀer,
“Controversies in ventricular remodelling,” The Lancet, vol.
367, no. 9507, pp. 356–367, 2006.
[112] J. N. Cohn, R. Ferrari, and N. Sharpe, “Cardiac remodeling-
concepts and clinical implications: a consensus paper from
an International Forum on Cardiac Remodeling,” Journal of
the American College of Cardiology, vol. 35, no. 3, pp. 569–
582, 2000.12 International Journal of Hypertension
[113] S. B. Gurley, A. Allred, T. H. Le et al., “Altered blood pressure
responses and normal cardiac phenotype in ACE2-null
mice,” Journal of Clinical Investigation, vol. 116, no. 8, pp.
2218–2225, 2006.
[114] M. J. Huentelman, J. L. Grobe, J. Vazquez et al., “Protection
from angiotensin II-induced cardiac hypertrophy and ﬁbro-
sisbysystemiclentiviraldeliveryofACE2inrats,”Experimen-
tal Physiology, vol. 90, no. 5, pp. 783–790, 2005.
[115] C. D´ ıez-Freire, J. V´ azquez, M. F. Correa De Adjounian et al.,
“ACE2 gene transfer attenuates hypertension-linked patho-
physiological changes in the SHR,” Physiological Genomics,
vol. 27, no. 1, pp. 12–19, 2006.
[116] K. Yamamoto, M. Ohishi, T. Katsuya et al., “Deletion of
angiotensin-converting enzyme 2 accelerates pressure over-
load-induced cardiac dysfunction by increasing local angiot-
ensin II,” Hypertension, vol. 47, no. 4, pp. 718–726, 2006.
[117] J. L. Grobe, A. P. Mecca, M. Lingis et al., “Prevention of
angiotensin II-induced cardiac remodeling by angiotensin-
(1-7),” American Journal of Physiology, vol. 292, no. 2, pp.
H736–H742, 2007.